2017 Data Shows Scope of ER/LA Opioid REMS CE Activities
The ACCME has released a data report showing the scope of continuing education activities offered by accredited providers within the ACCME Accreditation System in support of the US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics.
The report shows that 105 accredited CME providers reported 767 REMS-compliant activities educating nearly 208,500 learners since ACCME began collecting this data in 2013. The report includes information about the geographic distribution of activities, the activity types, and the percentages of activities designed and analyzed for changes in competence, performance, or patient outcomes.
The data report is made possible by the voluntary submission of ER/LA Opioid REMS data by accredited providers into ACCME’s Program and Activity Reporting System (PARS). As a service to the CME community and to the FDA, the ACCME modified PARS in 2013 to enable accredited providers to submit information specific to the REMS continuing medical education activities they provide.
The FDA REMS for ER/LA Opioid Analgesics is the first REMS to incorporate accredited continuing education (CE) about the risks of opioid medications as well as safe prescribing and safe use practices. The education is controlled, designed, and delivered by accredited continuing healthcare education providers.
The ACCME appreciates that the FDA recognizes the value of accredited education and chose to leverage the CE system to carry out this important public health initiative.